CMDN Editorial & Sourcing Policy
Committed to evidence-based transparency, delivering accessible and traceable myeloma knowledge for patients and families.
1. Platform Identity & Service Boundaries
China Myeloma Digital Network (CMDN) is a patient-founded information and navigation support network.
⚠️ Important Disclaimer: CMDN is not a medical institution, hospital, or clinic, and does not provide individualized clinical diagnosis, prescriptions, or treatment plans. All website content is for educational guidance only. Treatment decisions must follow professional oncologist advice.
2. 100% Evidence-Based Sourcing & Authority Links
All medical facts and clinical pathways on CMDN are 100% compiled from verifiable primary global sources. You may click the official links below to review primary publications:
World-leading developer of clinical practice guidelines in oncology
European consensus guidelines for multiple myeloma management
The global leader in patient support, education, and research for myeloma
Pioneering precision medicine and clinical trials for myeloma
Global expert consensus on myeloma diagnostic criteria and response assessment
Mayo Stratification for Myeloma and Risk-Adapted Therapy
3. Plain-Language Adaptation & AI Disclosure
To help patients and families navigate specialized medical jargon, CMDN adapts complex guidelines into accessible, plain language.
AI Tool Disclosure Statement:
- Artificial Intelligence (AI) tools are used strictly for formatting, translation support, and initial draft structuring.
- All drug names, dosages, indications, and clinical conclusions are word-for-word verified against primary literature by CMDN editors.
- Generative AI hallucinated medical claims without literature verification are strictly prohibited.
Feedback & Editorial Corrections
If you identify any data inaccuracy or have update suggestions, please contact our editorial team:
contact@chinamyeloma.org